RxDoctor Payments DataLook up a doctor →

Ghiath Mikdadi, MD

Cardiovascular Disease · Hammond, LANPI 1881696078

Payments from drug & device makers

$5,652,419in general payments, 2019–2025

Across 1,664 payments — averaging $3396.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$1.8M
  • American Regent$1.2M
  • Novartis$1.1M
  • Bayer$384K
  • AstraZeneca$257K
  • Boehringer Ingelheim International GmbH$256K
  • plus $690K from 52 others
$2,600in research payments, 2019–2025

Across 13 payments — averaging $200.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim International GmbH$1K
  • Eli Lilly$1K

What the payments were for

  • Consulting fees$3,2064%
  • Speaking & faculty fees$44,42058%
  • Travel & lodging$7,44310%
  • Food & beverage$21,23928%
  • Education$1670%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,652,419 in reported general payments places this provider in the 95th percentile of 281 cardiovascular disease providers in Louisiana.

See all cardiovascular disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$572,449
Medicare patients
1,150
Services billed
8,153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban757$584,847
EntrestoSacubitril/Valsartan587$476,422
XareltoRivaroxaban427$297,665
Repatha SureclickEvolocumab404$266,525
FarxigaDapagliflozin Propanediol277$177,946
JardianceEmpagliflozin151$129,146
VascepaIcosapent Ethyl226$108,610
BrilintaTicagrelor106$58,841
FuroscixFurosemide12$44,524
MultaqDronedarone Hcl36$43,975
NexlizetBempedoic Acid/Ezetimibe79$42,413
Ranolazine ErRanolazine219$12,638
Metoprolol Succinate1,170$11,960
OzempicSemaglutide13$11,839
Praluent PenAlirocumab22$11,126

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$869$584,847757 claims
NovartisEntresto$1,103,977$476,422587 claims
Johnson & JohnsonXarelto$969$297,665427 claims
AstraZenecaFarxiga, Brilinta$257,493$236,787383 claims
Boehringer IngelheimJardiance$1,794,480$129,146151 claims
Scpharmaceuticals Inc.Furoscix$4,508$44,52412 claims
Sanofi-aventis U.S. LLCMultaq$228$43,97536 claims
Esperion Therapeutics, Inc.Nexlizet$325$42,41379 claims
Novo NordiskOzempic$185$11,83913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 281 cardiovascular disease providers in Louisiana.

Other cardiovascular disease in Hammond

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →